Related Experiment Video
Updated: May 11, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch1, Diana C Hargreaves, Courtney Hodges
1Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
Abstract:
Subunits of mammalian SWI/SNF (mSWI/SNF or BAF) complexes have recently been implicated as tumor suppressors in human malignancies. To understand the full extent of their involvement, we conducted a proteomic analysis of endogenous mSWI/SNF complexes, which identified several new dedicated, stable subunits not found in yeast SWI/SNF complexes, including BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, BRD9 and SS18. Incorporating these new members, we determined mSWI/SNF subunit mutation frequency in exome and whole-genome sequencing studies of primary human tumors. Notably, mSWI/SNF subunits are mutated in 19.6% of all human tumors reported in 44 studies. Our analysis suggests that specific subunits protect against cancer in specific tissues. In addition, mutations affecting more than one subunit, defined here as compound heterozygosity, are prevalent in certain cancers. Our studies demonstrate that mSWI/SNF is the most frequently mutated chromatin-regulatory complex (CRC) in human cancer, exhibiting a broad mutation pattern, similar to that of TP53. Thus, proper functioning of polymorphic BAF complexes may constitute a major mechanism of tumor suppression.
Insights
Mammalian SWI/SNF (mSWI/SNF) subunits act as tumor suppressors. Mutations in these chromatin-regulatory complexes are found in nearly 20% of human cancers, highlighting their critical role in cancer suppression.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Mammalian SWI/SNF (mSWI/SNF) complexes, also known as BAF complexes, are increasingly recognized for their roles as tumor suppressors in human cancers.
- Understanding the complete subunit composition and mutation landscape of mSWI/SNF is crucial for elucidating their full impact on tumorigenesis.
Purpose of the Study:
- To perform a comprehensive proteomic analysis of endogenous mSWI/SNF complexes to identify novel subunits.
- To determine the mutation frequency of mSWI/SNF subunits across a wide range of human tumors.
- To investigate the tissue-specific roles and prevalence of compound heterozygosity in mSWI/SNF mutations.
Main Methods:
- Proteomic analysis of endogenous mSWI/SNF complexes to identify subunit composition.
- Analysis of exome and whole-genome sequencing data from primary human tumors to assess mutation frequency.
- Bioinformatic analysis to correlate subunit mutations with specific cancer types and tissues.
Main Results:
- Identification of several new stable subunits of mSWI/SNF complexes, including BCL7A, BCL7B, BCL7C, BCL11A, BCL11B, BRD9, and SS18.
- mSWI/SNF subunits are collectively mutated in 19.6% of human tumors across 44 studies.
- Specific subunits show protective roles in distinct tissues, and compound heterozygosity is common in certain cancers.
Conclusions:
- mSWI/SNF is the most frequently mutated chromatin-regulatory complex (CRC) in human cancer, with a mutation pattern similar to TP53.
- The proper function of polymorphic BAF complexes is essential for tumor suppression.
- These findings underscore the critical role of mSWI/SNF complexes in preventing cancer development.
More Related Videos
08:08Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Nucleolus